stock · yahoo

ABT

ABT

$99.60
▲ 1.11 (1.13%)
Last close · Oct 9

Below: live stock price for ABT (ABT), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

ABT (ABT) is a Healthcare company based in United States. Operating in Medical Devices, it employs about 122,000 people. Over the past year ABT traded between 81.97 and 133.34 USD. It currently yields 2.53% in dividends.

Day
+1.13%
+1.11
Week
-0.50%
-0.50
Month
-2.31%
-2.35
Year
—
Prev close
$98.49
Volume (24h)
—
Market cap
—
Currency
USD

Score

41/ 100 · Weak

Coverage: 7/7
  • Value43
  • Quality58
  • Momentum17
  • Growth24
  • Risk79
  • Dividend37
  • Liquidity27

Composite of public market data. Informational only — not investment advice.

Trend projection

Where the recent trend points if it continues.

DowntrendFit 16%Pace -0.11% per bar
+5 bars+20 bars+60 bars+120 bars
+5 bars
99.1548
-0.45%
Bull121.8059
Bear80.7159
+20 bars
98.5438
-1.06%
Bull148.7094
Bear65.301
+60 bars
98.3084
-1.30%
Bull200.5045
Bear48.2012
+120 bars
98.2998
-1.31%
Bull269.3388
Bear35.8762

Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.046 USD.

Interpretation

Composite signals look weak. Strength: risk profile with weakness: momentum. Price sits near the lower third of the recent range, trend is sloping downward.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

  • Value
    43/100

    Value looks weak — driven by P/E (32.84).

    P/E:32.84P/B:3.45PEG:1.83
  • Quality
    58/100

    Quality looks mixed — driven by Gross margin (56.85%).

    ROE:10.58%ROA:5.33%Profit margin:11.65%Gross margin:56.85%
  • Momentum
    17/100

    Momentum looks fragile — driven by 52w change (-24.19%).

    52w change:-24.19%
  • Growth
    24/100

    Growth looks fragile — driven by Earnings growth (-47.50%).

    Revenue growth:13.00%Earnings growth:-47.50%
  • Risk
    79/100

    Risk looks strong — driven by Debt / equity (63.21).

    Beta:0.58Debt / equity:63.21Short interest:0.88%
  • Dividend
    37/100

    Dividend looks weak — driven by Payout ratio (78.71%).

    Dividend yield:2.53%Payout ratio:78.71%
  • Liquidity
    27/100

    Liquidity looks fragile — driven by Current ratio (1.38).

    Current ratio:1.38Quick ratio:0.8

Derived from public market data — informational, not investment advice.

Price report

How this asset has actually moved over the last 250 days.

Position in range34%
81.97 low133.34 high

Where the price sits between the window low and high.

Volatility (annualised)
27.3%

Spread of returns. Higher means larger swings in both directions.

Max drawdown
-38.1%

Worst peak-to-trough fall inside the window.

Below period high
-25.3%

Current price against the highest point in the window.

Best day
+10.71%
Worst day
-10.04%
Up days
47%

Share of days that closed above the one before.

Current streak
1 up
Typical day swing
2.2%

Average high-to-low spread within a single day.

Volume vs average
-14%

Last 10 days against the whole window.

Descriptive statistics over past prices — not a forecast and not investment advice.

Reference levels

Fibonacci retracements and extensions across the recent range.

60 bars

Reference only — not investment advice.

These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.

Next level above
99.8279 USD+0.23%
Fib 78.6% retracement
Next level below
88.9998 USD-10.64%
Fib −27.2% extension

Levels derived from: 117.34 high → 95.06 low · 60 bars

  • Resistance
    Fib +161.8% extension
    not reached
    153.389 USD
    +54.01% from current
  • Resistance
    Fib +100% extension
    not reached
    139.62 USD
    +40.18% from current
  • Resistance
    Fib +61.8% extension
    not reached
    131.109 USD
    +31.64% from current
  • Resistance
    Fib +27.2% extension
    not reached
    123.4002 USD
    +23.90% from current
  • Resistance
    Fib 23.6% retracement
    tested 6×
    112.0819 USD
    +12.53% from current
  • Resistance
    Fib 38.2% retracement
    tested 9×
    108.829 USD
    +9.27% from current
  • Resistance
    Fib 50% midpoint
    tested 8×
    106.2 USD
    +6.63% from current
  • Resistance
    Fib 61.8% retracement
    tested 9×
    103.571 USD
    +3.99% from current
  • Resistance
    Fib 78.6% retracementNearest
    tested 7×
    99.8279 USD
    +0.23% from current
  • Current
    99.6 USD
  • Support
    Fib −27.2% extension
    not reached
    88.9998 USD
    -10.64% from current
  • Support
    Fib −61.8% extension
    not reached
    81.291 USD
    -18.38% from current
  • Support
    Fib −100% extension
    not reached
    72.78 USD
    -26.93% from current
How to read this

We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.

“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.

This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.

Financials

52w high
$133.34
52w low
$81.97
52w change
-24.19%
Day high
$101.82
Day low
$99.78
P/E (TTM)
32.84
Forward P/E
16.79
PEG
1.83
Price / Book
3.45
Beta (5Y)
0.58
Enterprise value
200.12B
EV / Revenue
4.3
EV / EBITDA
17.13
EPS (TTM)
$3.10
Forward EPS
$6.06
Dividend yield
2.53%
Dividend rate
$2.52
Payout ratio
78.71%
Revenue (TTM)
46.58B
EBITDA
11.68B
Free cash flow
7.21B
Total cash
5.6B
Total debt
32.72B
Debt / Equity
63.21
Current ratio
1.38
Quick ratio
0.8
Profit margin
11.65%
Gross margin
56.85%
Return on assets
5.33%
Return on equity
10.58%
Shares outstanding
1.74B
Float
1.72B
Sector: HealthcareIndustry: Medical DevicesHQ: United StatesEmployees: 122Kwww.abbott.com

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Analyst & Risk

Consensus
Strong Buy
Mean rating1.46 / 5
Analysts26
Next earnings2026-10-21
Strong buy 5Buy 19Hold 4
Analyst price target
$120.72
Mean target · 26 analysts
+21.2%
upside
Low $103.00Now $99.60High $135.00
Beta (vs S&P 500)
0.58
less volatile
52-week change
-24.19%
Short % of float
0.88%
Short ratio (days)
1.57
Debt / Equity
63.21
very high leverage
Current ratio
1.38
Quick ratio
0.8
ROE
10.58%
ROA
5.33%
PEG ratio
1.83
fair
EV / Revenue
4.3
EV / EBITDA
17.13
Revenue growth
13.00%
Earnings growth
-47.50%
EBITDA
11.68B
Free cash flow
7.21B
Total cash
5.6B
Total debt
32.72B
Insider holdings
0.49%
Institutional
81.79%

Recent rating changes

  • 2026-10-07BarclaysOverweightinit
  • 2026-10-02Rothschild & CoNeutral → Buyup
  • 2026-09-08TD CowenBuy → Buyreit
  • 2026-08-25TD CowenBuy → Buymain
  • 2026-08-21TD CowenBuy → Buymain
  • 2026-08-14CitigroupBuy → Buymain
  • 2026-08-13Wolfe ResearchPeer Perform → Outperformup
  • 2026-07-28UBSBuy → Buymain

Recent news

Related

Other assets in this category.

Learn the terms

Live discussion

Sign in to join the discussion.

  • No comments yet. Be the first.